Products for Research Use Only

Samidorphan-d4

CAT: 0804-HY-123689SSize: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-123689SSize:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Samidorphan-d4 is the deuterium labeled Samidorphan.Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo[1].
Product Name Alternative
ALKS-33-d4; RDC-0313-d4
UNSPSC
12352005
Target
Isotope-Labeled Compounds; Opioid Receptor
Type
Isotope-Labeled Compounds
Related Pathways
GPCR/G Protein; Neuronal Signaling; Others
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Smiles
O=C(N)C1=CC=C(C[C@H]([C@@]2(CC3)O)N(CC4)CC5C([2H])([2H])C5([2H])[2H])C([C@]42CC3=O)=C1O
Molecular Formula
C21H22D4N2O4
Molecular Weight
374.47
References & Citations
[1]Mark S. Todtenkopf, et al. Buprenorphine in Combination with Samidorphan (ALKS 33) Results in Antidepressive-Like Effects in Two Distinct Rat Models. Eur Neuropsychopharmacol. 2014;24aSuppl 2) :S366.|[2]McElroy SL, et al. A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder. Int J Eat Disord. 2013 Apr;46 (3) :239-45.|[3]Rehan ST, et al. Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials. Ann Med Surg (Lond) . 2022 Jun 30;79:104115.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported